Status:
UNKNOWN
C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine Effectiveness in Metastatic Colon Cancer
Lead Sponsor:
Universidad de Costa Rica
Collaborating Sponsors:
Universitat Autonoma de Barcelona
Conditions:
Colon Cancer
MTHFR Gene Mutation
Eligibility:
All Genders
18+ years
Brief Summary
Fluoropyrimidines are the backbone of chemotherapy regimes used to treat metastatic colorectal cancer (CRC). These drugs act in different pathways of folate metabolism altering DNA synthesis mainly by...
Detailed Description
Patients with metastatic colorectal cancer are invited to join this study at the start of treatment with any fluoropyrimidine used alone or in combination with oxaliplatin and/or irinotecan +/- bevaci...
Eligibility Criteria
Inclusion
- Patients with metastatic colorectal cancer receiving first line therapy with any fluoropyrimidine (capecitabine or 5-Fluorouracil) alone or in association with oxaliplatin, and/or irinotecan, plus either bevacizumab or cetuximab/panitumumab.
Exclusion
- Any other malignant condition
Key Trial Info
Start Date :
January 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT03852290
Start Date
January 16 2019
End Date
October 1 2021
Last Update
March 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital San Juan de Dios
San José, Costa Rica, 1000